Tuesday, June 18, 2024

Elevated IL-17 Levels Linked to Increased Risk of Ischemic Cardiovascular Disease

Similar articles

Interleukin-17 (IL-17) has long been speculated to play a role in ischemic cardiovascular disease (ICVD), yet definitive evidence has remained elusive. A recent study aimed to clarify this relationship through a comprehensive meta-analysis, shedding new light on the potential role of IL-17 as a risk marker for ICVD. This investigation synthesized data from multiple studies, revealing significant findings that could influence future research directions and therapeutic strategies.

A systematic review of the PubMed, Web of Science, Cochrane Library, and Embase databases up to October 2023 identified 955 publications on IL-17 and ICVD. Following rigorous screening, six studies were included in the final meta-analysis. The average age of participants was 60.3 ± 12.6 years, with 65.5% being men. The analysis revealed considerable heterogeneity among the selected studies.

Study Findings

The meta-analysis demonstrated that IL-17 levels were significantly elevated in individuals with ICVD compared to control groups. Specifically, the standardized mean difference (SMD) was 1.60, with a 95% confidence interval ranging from 0.53 to 2.66, and a P-value of 0.003. This suggests a strong association between heightened IL-17 levels and ICVD. Sensitivity analyses confirmed the robustness of these findings.

Factors Influencing Study Heterogeneity

Subgroup analyses revealed that race and ethnicity, sample size, and detection methods significantly influenced the heterogeneity observed among the studies. These factors need to be carefully considered in future research to ensure the accuracy and applicability of the findings across diverse populations.

Practical Implications

The study’s results offer valuable insights for both clinicians and researchers:

  • Elevated IL-17 levels could serve as a biomarker for early detection of ICVD, allowing for timely intervention.
  • Tailoring ICVD treatment approaches based on IL-17 levels may improve patient outcomes.
  • Future research should focus on standardizing detection methods to reduce heterogeneity and enhance study comparability.

In conclusion, the study underscores the potential of IL-17 as a risk marker for ICVD, highlighting the need for further research. Establishing IL-17 as a therapeutic biomarker could pave the way for targeted treatment strategies, ultimately improving patient care.

Original Article: BMC Cardiovasc Disord. 2024 May 16;24(1):252. doi: 10.1186/s12872-024-03897-w.

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article